Digital Stratification of BAP1-mutant Cancers (BAP-1)

Development of Digital Biomarkers for BAP1 Mutated Cancers (German Cancer Aid)

The project centers around BAP1, a tumor suppressor gene often mutated in aggressive cancers. Specifically, BAP1 mutations lead to increased tumor aggressiveness and metastasis. The goal of this project is to understand and target a vulnerability of BAP1 mutations for potential therapies in BAP1-mutant cancers. To achieve this, a collaborative consortium has been formed with subprojects focusing on providing necessary materials, testing specific drugs in vitro, in vivo and in patient-derived organoids, as well as conducting biomarker analyses on large human tissue cohorts. The overall aim is to validate the proposed mechanism and explore potential treatments, with an emphasis on initiating clinical trials based on the findings. The project integrates diverse approaches, including in vitro, in vivo, ex vivo, and clinical sample analyses, to comprehensively investigate BAP1-mutant cancers and develop personalized medicine strategies. Within this consortium, our group is responsible for digital biomarker development for improved patient stratification.